Mineralys Therapeutics to present new lorundrostat Launch-HTN data at ASN Kidney Week 2026

MLYS•2026-10-02

Mineralys Therapeutics said new Launch-HTN data show lorundrostat reduced blood pressure and improved albuminuria in patients with chronic kidney disease stages 1 to 3; the data will be presented Oct. 21-25 in Denver.

1. Trial data presentation

Mineralys Therapeutics disclosed that new Launch-HTN trial data on lorundrostat will be presented at ASN Kidney Week 2026 in Denver, Oct. 21-25. The results show lorundrostat reduced blood pressure, with a separate improvement in albuminuria, among patients with chronic kidney disease stages 1 to 3.

Mineralys Therapeutics to present new lorundrostat Launch-HTN data at ASN Kidney Week 2026

1. Trial data presentation

Related News

Danaher files Form 3 for SVP, Chief Strategy Officer Shashanka Muppaneni

Halozyme names James M. Daly as director

H&R Block Chief Retail Officer Mark J. Darling sells 2,700 shares for $109,852.74

UGI unit issues $30 million of 5.95% senior notes due Sept. 28, 2038

Tonix says Dr. Reddy’s files generic TONMYA challenge with Paragraph IV patent notice